Acumen's Enhanced Brain Delivery candidates achieved 14-40x higher antibody concentrations in primate brains, advancing its Alzheimer's platform ahead of...

FDA accepts Outlook's LYTENAVA resubmission for wet AMD with Class 1 review status and a July 29, 2026 PDUFA...

Rigel Acquires Global Rights to Breast Cancer Drug VEPPANU for $70M just six weeks after FDA approval, targeting August...

Isomorphic Labs' $2.1B raise signals AI drug discovery has crossed from hype to pipeline — and traditional pharma R&D...

Reunion Neuroscience names operator Sahil Kirpekar as CEO following luvesilocin breakthrough designation for postpartum depression treatment.

Setmelanotide pediatric hypothalamic obesity treatment showed 71% of patients improved by at least one weight category after one year,...

Adaptive Biotechnologies separates its profitable $145M MRD diagnostics unit from its AI-driven TCR platform, betting two focused stories beat...

Scilex distributes Semnur Pharmaceuticals spinout on June 15, separating its sciatica-focused pipeline from commercial operations.

Tzield's FDA approval for stage 3 type 1 diabetes creates a new disease-modifying therapy category for 2.1M U.S. patients...

Intravacc and SynphaBase partner to address synthetic oligosaccharide supply and GMP manufacturing gaps in conjugate vaccine development.